Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
Constellation Pharmaceuticals (Nasdaq: CNST) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:00 PM EDT. CEO Jigar Raythatha will present, and a live audio webcast will be accessible on the company's Investor Relations website. This event highlights Constellation's commitment to developing novel therapeutics targeting cancer through epigenetics. The company is advancing its candidates, including the BET inhibitor pelabresib (CPI-0610) and the EZH2 inhibitor CPI-0209, aimed at addressing unmet medical needs in cancer treatment.
- None.
- None.
CAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference. Jigar Raythatha, president and chief executive officer, will present at the Jefferies Virtual Healthcare Conference at 3:00 PM EDT on June 3. Live audio webcast of Mr. Raythatha’s presentation and archives for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replays will be available for 90 days following the live presentation.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor pelabresib (CPI-0610) for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Contact
Kia Khaleghpour, Ph.D.
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com
Helen O’Gorman
FTI Consulting
+1 718-408-0800
Helen.O’Gorman@fticonsulting.com
FAQ
What is Constellation Pharmaceuticals' upcoming event on June 3, 2021?
Who will present at the Jefferies Virtual Healthcare Conference for Constellation Pharmaceuticals?
How can I access the Constellation Pharmaceuticals presentation?
What are the main products being developed by Constellation Pharmaceuticals?
How long will the audio webcast of the presentation be available?
